Snow Lake Lithium Provides Final Update Following Successful Completion of the 2022 Grass River Drilling Campaign theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Results:2.0 % Li2O over 16 meters starting at 30.9 meters down hole (CBP-007)Including 3.1 % Li2O over 1.5 meters1.8 % Li2O over 3.0 meters starting at 210.3 meters down hole (GRP-018)Including 3.6 % Li2O
/PRNewswire/ The "Toxicology Services Global Market - Forecast to 2028" report has been added to ResearchAndMarkets.com s offering. According to analysis,.
Updated:
Share Article
AAA
Dr. Reddy’s Laboratories Canada Inc., on behalf of a consortium, has filed an application with Health Canada seeking authorisation for Reeqonus (favipiravir) tablets for the acute treatment of mild to moderate COVID-19 adult patients. “Dr. Reddy’s is working closely with Health Canada for an expedited review of the drug application as speed to market is essential”, VP and general manager Vinod Ramachandran said. “If approved, it will launch the product soon for COVID-19 patients in Canada,” he added.
Dr. Reddy’s Canada has filed the application on behalf of the consortium comprising Dr. Reddy’s Laboratories, Appili Therapeutics and Global Response Aid FZCO (GRA) under Health Canada’s interim order “respecting the importation, sale and advertising of drugs for use in relation to COVID-19.”
Dr Reddy s labs, its subsidiaries announces filing application for REEQONUS™ (favipiravir) Tablets
Hyderabad, Dec 22 (UNI) Dr. Reddy’s Laboratories Limited, along with its subsidiaries together referred to as “Dr. Reddy’s”, Appili Therapeutics and Global Response Aid FZCO (GRA) on Tuesday announced that Dr. Reddy’s Canada has filed an application on behalf of the consortium for REEQONUS™ (favipiravir) Tablets.
The REEQONUS™ (favipiravir) Tablets was for the acute treatment of mild to moderate COVID-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.
REEQONUS™ is also known as Avigan® (favipiravir) Tablets developed by FUJIFILM Toyama Chemical Company Limited, the Pharma Company said in a release here.